The global canagliflozin market is primarily driven by the increasing prevalence of type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). According to the International Diabetes Federation, approximately 537 million adults worldwide were living with diabetes in 2021, and this number is expected to rise to 783 million by 2045. Canagliflozin, as an SGLT2 inhibitor, plays a significant role in managing T2DM by improving glycemic control, and it is also approved for reducing the risk of cardiovascular events in diabetic patients. Moreover, the growing burden of CKD, which affects an estimated 700 million people globally, further strengthens the demand for Canagliflozin, especially as it has demonstrated efficacy in slowing the progression of kidney disease. These factors, along with rising awareness about the drug's dual benefit in diabetes and renal care, are contributing to its widespread adoption across various healthcare settings.
